is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
What role has CPhI Japan played in your company’s success?
We exhibited at CPhI Japan, met potential clients at our booth and gave presentations at the exhibitor’s seminar. This gave us many opportunities to meet new customers as well as [...]
CPhI Japan – organised by Informa Markets and UBM Japan – announces that the event will be postponed after an extensive consultation with key stakeholders and consideration of all alternatives.
Given your expertise, how would you asses the present state of the Japanese market? At present, the pharma industry in Japan is facing a challenging situation. Japan has a rapidly aging population...
Planning on joining us at CPhI Japan? Whether you’re a visitor or exhibitor, it’s likely that you’ll have plenty of meetings to attend onsite. When visiting Japan – particularly with the aim of doing...
Japanese culture has a profound impact on decision-making and ultimately business relationships. We’ve gathered some tips below, to make sure you make the best first impression possible at CPhI Japan.
This report highlights trends in Japan’s pharma market, notably how costly, long-listed products will be replaced due to generic and biosimilar industries continuing to grow in volume and market share. It also discusses increased internationalisation of innovation, with a rise in acquisitions and partnerships with academia.
Wondering if CPhI Japan and its co-located events are the right platform for your business? Download our 2019 post-show report today to get an in-depth look at the audience you can expect to meet onsite.
Japan has the world’s third largest pharma industry. Yet, for many international companies the market has not proved easy to access. Very high barriers to entry have combined with a historically insular domestic market to limit opportunities. This is now changing. Japan’s domestic market is looking increasingly at exports, and international companies are seeking opportunities to invest in and access the large, well-funded healthcare system.